{"article_title": "Reasons for Alpha Blocker Switch ID'd", "article_keywords": ["prescription", "efficacy", "reasons", "blocker", "taking", "patients", "switch", "pusan", "reason", "alpha", "idd", "main"], "article_url": "http://www.renalandurologynews.com/news-in-brief/reasons-for-alpha-blocker-switch-idd/article/363862/", "article_text": "Reasons for Alpha Blocker Switch ID'd\n\nShare this content:\n\n\n\nlinkedin\n\ngoogle\n\n\n\nEmail\n\nPrint\n\n\n\nLack of efficacy is the main reason for the switch.\n\nAbout one-fifth of patients prescribed an alpha blocker for lower urinary tract symptoms suggestive of benign prostatic hyperplasia have their prescription changed to another alpha blocker, and lack of efficacy is the main reason for the switch, according to a new study published online ahead of print in Urology.\n\nTae Nam Kim, MD, of Pusan National University Hospital in Pusan, Korea, and colleagues studied 3,200 patients who took 1 of 4 different alpha blockers (doxazosin, alfuzosin, tamsulosin, and silodosin). Of these patients, 694 (21.7%) had a prescription change to another alpha blocker after taking their first one for a mean 10.8 weeks.\n\nReasons for the change were lack of efficacy (52.7%), adverse events (33.1%), cost (7.0%), inconvenience of taking the drug (4.1%), and cardiovascular morbidity (3.2%).", "article_metadata": {"com.silverpop.brandeddomains": "www.pages05.net,cancertherapyadvisor.com,chemotherapyadvisor.com,clinicaladvisor.com,clinicalpainadvisor.com,empr.com,endocrinologyadvisor.com,infectiousdiseaseadvisor.com,mycme.com,neurologyadvisor.com,oncologynurseadvisor.com,psychiatryadvisor.com,renalandurologynews.com", "news_keywords": "Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia, Urinary Tract Infection, Urinary Tract Infection", "content-language": "en-US", "og": {"site_name": "RUN", "description": "Lack of efficacy is the main reason for the switch.", "title": "Reasons for Alpha Blocker Switch ID'd", "url": "http://www.renalandurologynews.com/news-in-brief/reasons-for-alpha-blocker-switch-idd/article/363862/", "image": "http://media.renalandurologynews.com/images/2014/05/16/122467820_593807_593808.png", "type": "article"}, "twitter": {"site": "@renalandurology", "image": {"src": "http://media.renalandurologynews.com/images/2014/05/16/122467820_593807_593808.png"}, "description": "Lack of efficacy is the main reason for the switch.", "card": "summary_large_image", "title": "Reasons for Alpha Blocker Switch ID'd"}, "apple-itunes-app": "app-id=587062895", "fb": {"app_id": 200400499974989}, "google-site-verification": "JDgj8jDFIzEu5m2voDjw3__aZEqn00uBw9BN1Hv8PzY", "article": {"section": "News in Brief", "tag": "Urinary Tract Infection", "published_time": "2014-08-02T09:00:00", "modified_time": "2014-07-31T14:44:39"}, "Content-Type": "text/html", "viewport": "width=device-width, initial-scale=1.0", "description": "Lack of efficacy is the main reason for the switch."}, "article_summary": "Reasons for Alpha Blocker Switch ID'dShare this content:linkedingoogleEmailPrintLack of efficacy is the main reason for the switch.\nOf these patients, 694 (21.7%) had a prescription change to another alpha blocker after taking their first one for a mean 10.8 weeks.\nAbout one-fifth of patients prescribed an alpha blocker for lower urinary tract symptoms suggestive of benign prostatic hyperplasia have their prescription changed to another alpha blocker, and lack of efficacy is the main reason for the switch, according to a new study published online ahead of print in Urology.\nReasons for the change were lack of efficacy (52.7%), adverse events (33.1%), cost (7.0%), inconvenience of taking the drug (4.1%), and cardiovascular morbidity (3.2%).\nTae Nam Kim, MD, of Pusan National University Hospital in Pusan, Korea, and colleagues studied 3,200 patients who took 1 of 4 different alpha blockers (doxazosin, alfuzosin, tamsulosin, and silodosin)."}